Neuroendocrine tumors are rare, accounting for less than 1% of all malignant tumors, and most of them occur in the stomach, intestines, and pancreas. The most common type of cancer in this type of tumor is carcinoid, with an incidence of about 2.5/100000, accounting for 50% of all gastrointestinal pancreatic neuroendocrine tumors. Carcinoid tumors can be divided into anterior intestine (lung, lung, Bronchus and upper gastrointestinal tract up to jejunum), midgut (ileum and appendix) and hindgut (rectum and rectum). Such tumors can occur in the entire neuroendocrine system, but the most common site of involvement is the pancreas. Neuroendocrine tumors can be divided into two major categories according to whether the substances secreted by the tuberculum cause typical clinical symptoms mdash; mdash; functional and non-functional.
Currently, in curatio ad neuroendocrine tumores in mundo est plurimum peptide receptor radionuclide Lorem (PRRT). Et haec est articulum scriptum est in medico est peptide receptor radionuclide American Lorem:
Quid est Lorem peptide receptor Human (PRRT)?
Quid est Lorem peptide receptor radionuclide (PRRT) et quomodo operatur?
Lorem peptide receptor radionuclide (PRRT) Lorem sit hypothetica relatas (Pisces quoque vocatur Lorem) facies ad specifica genera cancer, et vocavit malignancies Neuroendocrine neuroendocrine tumores (neuroendocrine tumores). Lorem peptide receptor radionuclide (PRRT) is quoque studium desit in curatio de prostate et pancreaticum tumores.
Receptoris radionuclidis in peptide therapia (PRRT), interdum (vel peptide) dicta cellula targeting quae octreotide vocatur, coniuncta cum parva dose materiae radioactivae, seu radionuclidis, specialem rationem efficit radiopharmaceuticae quod vocatur peptidium radioactivum. Cum infusum in sanguinem aegri, haec radioactivitas intrat et ad cellas tumori neuroendocrinas applicat, summus dosis radiotherapy laesionem cancri dans.
Maxime in neuroendocrine tumore cellulis, locupletandum (overexpression vocatur) habeat species specialissimas numerus superficies, & receptores hac in cellula distribui dapibus sit a hormone-superficies est coniuncta cum corpore dicitur incrementum hormone machinationem inhibendi ius elementum. Octreotide summatim perstringitur a hormone in officinarum, qui machinationem inhibendi ius attachiatus ad neuroendocrine tumor incrementum hormone receptor. In Lorem peptide receptor radionuclide (PRRT), octreotide combined per curationis doses radionuclide XC-Yttrium (Y-XC) et CLXXVII Lutetium (Lu-CLXXVII), est plerumque adsuesco assuesco radionuclide.
Quod morbis tractari possunt ex peptide receptor radionuclide Lorem (PRRT)?
Is peptide receptor radionuclide therapy ( PRRT) used to treat neuroendocrine tumors? (NETs), including carcinoidei tumores, pancreatic islet cell carcinoma, small cell lung cancer, pheochromocytoma (a rare tumor formed in the adrenal glands), stomach-intestine-pancreas (stomach, intestine and pancreas) neuroendocrine tumors, And rare thyroid cancer that does not respond to radioactive iodine therapy.
Lorem peptide receptor radionuclide (PRRT) aegris est optio:
• Quod est provecta patientes estote et / vel provectus neuroendocrine tumores
• qui sunt aegroti, aeque aut surgery
Respondeo dicendum quod symptoms non est • patientes estote ad aliud medicamentum
Quod principalis finis est Lorem peptide receptor radionuclide (PRRT) Est ad auxilium levare salubria, quod subsisto sive meliorem altiore progressum mora tumore salvos.
Quid est Lorem peptide receptor radionuclide (PRRT) opus?
Fretus typus of cancer curatio processus exsequendam esse tractata et curatio apparatu, aegris potest recipere usque ad X radionuclide Lorem cursus peptide receptor (PRRT), separata intra, 10-2 mensibus. Fretus radionuclide de Lorem rationem locorum, et non implemented, hoc remedio utendum est outpatient curatio potest procedure, vel paucis diebus ut requirere hospitalis curatio.
Tumor omnis peptide receptor illic (PRRT) incipit cum amino acida tueri facile patiente renes infunditur intravenously ex irradiatione. Deinde ardens missus est enim precursor patientes estote ad infusum, sequitur additional amino acidum solutio. In totalis et curatio spatium fere IV horas pugnatum.
Per subsequent treatments, ex imagine hypothetica visu perlustrat ut qua sibimet exhiberi observe infusum ardens missus precursor ingressus est corporis, etsi non haec amet.
Quod sunt commoda peptide receptor radionuclide Lorem (PRRT)?
Peptide receptor radionuclidis therapiae (PRRT) et aliae therapiae hypotheticae plus possunt curationi cancri individuatae, quia radiopharmaceutica adaptari possunt secundum singulares indoles biologicas patientis et notas hypotheticas tumoris. Peptide receptaculum radionuclidis therapiae (PRRT) etiam therapia iaculis aestimatur, quia peptides radioactivae facultatem habent ut cellulis tumoris neuroendocrinarum selective destruantur, dum nudationem radiorum textus normalem limitant. Ergo in genere, peptide receptor radionuclidis therapiae (PRRT) habet effectus latus respective ad chemotherapy comparatum.
Lorem peptide receptor radionuclide (PRRT) species est, cum a excelsum de tumor efficaciam ex treatment options ad neuroendocrine imperium provectus, progressivus. Lorem peptide receptor radionuclide (PRRT) Non enim curationum remedio, sed iam ostensum est mora morbus auxilium progressum symptoms et habet sublevantem.
Peptide receptor radionuclide est Lorem (PRRT) tutum?
Omnes treatments, inter peptide receptor radionuclide Lorem (PRRT), latus effectus, et non metus. Quid de te ad extrema temptaturum et beneficia peptide receptor radionuclide Lorem (PRRT) treatment cum vestris provisor, tum alia treatments es considerans. Ex vestri medical historia, curatio vestra provisor auxiliatus sum tibi decernere, utrum vel non peptide receptor radionuclide Lorem (PRRT) electionis est maxime verum. Vide certiorem vestra provisor circa alia curatio curatio ante te accepimus, ut hic magni momenti locus in recta pronuntiatione circa medicamento curatio et dosage.
De parte effectus peptide receptor radionuclide Lorem (PRRT)?
Lorem peptide receptor radionuclide (PRRT) optime se non tolerantur, sed per injectiones amino acidum, aegris habent plerumque nauseam et vomitum (interdum gravibus admodum). Hoc postulat anti-curatio nauseam aut tarditatem in rate of amino acidum administratione. Et iam ad terminum, non parte effectus includit sanguis comitem a constant. Altiore, hoc est curatio bene toleratur a maxime aegris.
Curam domi
Medicinae facilitas tua providebit vos cum aliquo dirigente ad sequens curatio. Rectum enim parvum quantum non in corpore, patiatur necesse est aegris alius treatment post 1-2 dies post peptide receptor radionuclide Lorem (PRRT). Quod a reliquo corpore exeant radionuclides urinam feces secretum bonae valetudinis curandae interest servare debuerit.
Quae sunt novae progressiones in investigatione peptide receptoris radionuclidis therapiae (PRRT) ?
Peptide receptor radionuclidis therapiae (PRRT) Investigatio nunc in peracta periodo III clinicis iudiciis feruntur et sperat US FDA recipiendi approbationem pro suis indiciis paulo post. Investigationes permanentes etiam investigationem de his applicationibus comprehendunt:
• Usus duorum simul peptides
• Radioactive peptides treatments cum aliis chemotherapy
Rectum applicationem • Repetita
• Numerum indiciorum ad hoc genus radiorum curationis augendum, inclusis aliis morbis scutis
Other • radionuclide, precursor usum communem.
